Catalyst Pharma Says FIRDAPSE NDA Submitted In Japan By Partner DyDo Pharma
(RTTNews) - Biopharmaceutical company Catalyst Pharmaceuticals, Inc. (CPRX) announced Monday that its collaboration partner, Japan's DyDo Pharma, Inc., reported that it has submitted a New Drug Application (NDA) to the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan, seeking marketing approval for FIRDAPSE (amifampridine) Tablets 10 mg for the treatment of Lambert Eaton myasthenic syndrome (LEMS) in Japan.
The submission is based on preliminary favorable analysis results of interim data after six months into the safety phase of the registration study to evaluate the efficacy and safety of FIRDAPSE for the treatment of LEMS.
The review period is expected to be approximately a minimum of nine months from the submission date.
In June 2021, Catalyst entered into a license agreement with DyDo for the development and commercialization of FIRDAPSE in Japan.
Catalyst Pharma Appoints Richard Daly To Succeed Patrick McEnany As CEO
TSX Hits New Record High As Stocks Rally On Fed Rate Cut Hopes
Powell Says Outlook, Shifting Balance Of Risks 'May Warrant' Lower Rates
Bay Street Likely To Open On Mixed Note; Powell's Speech Eyed
Sensex, Nifty Snap Six-day Winning Streak On Tariff Concerns
FTSE 100 Down Slightly; Standard Chartered Shares Up Sharply
U.S. Dollar Rises Ahead Of Fed's Powell Speech
